PL2365987T3 - Przeciwciała anty-HER4 swoiste dla określonej izoformy - Google Patents

Przeciwciała anty-HER4 swoiste dla określonej izoformy

Info

Publication number
PL2365987T3
PL2365987T3 PL09760430T PL09760430T PL2365987T3 PL 2365987 T3 PL2365987 T3 PL 2365987T3 PL 09760430 T PL09760430 T PL 09760430T PL 09760430 T PL09760430 T PL 09760430T PL 2365987 T3 PL2365987 T3 PL 2365987T3
Authority
PL
Poland
Prior art keywords
specific anti
isoform specific
her4 antibodies
her4
antibodies
Prior art date
Application number
PL09760430T
Other languages
English (en)
Inventor
Mark X Sliwkowski
Klaus Elenius
Maija Hollmen
Original Assignee
Genentech Inc
Univ Of Turku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Of Turku filed Critical Genentech Inc
Publication of PL2365987T3 publication Critical patent/PL2365987T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09760430T 2008-11-25 2009-11-24 Przeciwciała anty-HER4 swoiste dla określonej izoformy PL2365987T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11790308P 2008-11-25 2008-11-25
EP09760430.0A EP2365987B1 (en) 2008-11-25 2009-11-24 Isoform specific anti-her4 antibodies
PCT/US2009/065712 WO2010068437A1 (en) 2008-11-25 2009-11-24 Isoform specific anti-her4 antibodies

Publications (1)

Publication Number Publication Date
PL2365987T3 true PL2365987T3 (pl) 2015-04-30

Family

ID=42021645

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09760430T PL2365987T3 (pl) 2008-11-25 2009-11-24 Przeciwciała anty-HER4 swoiste dla określonej izoformy

Country Status (15)

Country Link
US (2) US20110293614A1 (pl)
EP (1) EP2365987B1 (pl)
JP (1) JP5894436B2 (pl)
KR (1) KR101789338B1 (pl)
CN (2) CN109608545A (pl)
AU (1) AU2009324939B2 (pl)
BR (1) BRPI0916092A2 (pl)
CA (1) CA2744512C (pl)
DK (1) DK2365987T3 (pl)
ES (1) ES2528929T3 (pl)
IL (1) IL212900A0 (pl)
MX (1) MX2011005382A (pl)
PL (1) PL2365987T3 (pl)
SI (1) SI2365987T1 (pl)
WO (1) WO2010068437A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009324939B2 (en) 2008-11-25 2015-07-09 Genentech, Inc. Isoform specific anti-HER4 antibodies
US10083108B1 (en) * 2017-12-18 2018-09-25 Clover Network, Inc. Automated stack-based computerized application crawler
CN112753956A (zh) * 2021-01-20 2021-05-07 重庆周师兄餐饮文化有限公司 一种腰片的加工方法
CN113999228B (zh) * 2021-11-08 2022-11-04 南京卓康医药科技有限公司 一种他达拉非的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69740038D1 (pl) 1996-07-12 2010-12-16 Genentech Inc
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
AU9805398A (en) * 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
AU2009324939B2 (en) 2008-11-25 2015-07-09 Genentech, Inc. Isoform specific anti-HER4 antibodies

Also Published As

Publication number Publication date
AU2009324939B2 (en) 2015-07-09
IL212900A0 (en) 2011-07-31
KR101789338B1 (ko) 2017-10-23
WO2010068437A1 (en) 2010-06-17
ES2528929T3 (es) 2015-02-13
KR20110098756A (ko) 2011-09-01
AU2009324939A1 (en) 2010-06-17
CA2744512A1 (en) 2010-06-17
JP5894436B2 (ja) 2016-03-30
US20160075798A1 (en) 2016-03-17
DK2365987T3 (en) 2015-01-12
MX2011005382A (es) 2011-07-20
CN102725310A (zh) 2012-10-10
BRPI0916092A2 (pt) 2015-11-17
US20110293614A1 (en) 2011-12-01
JP2012509896A (ja) 2012-04-26
EP2365987B1 (en) 2014-11-12
SI2365987T1 (sl) 2015-03-31
CN109608545A (zh) 2019-04-12
US9963517B2 (en) 2018-05-08
EP2365987A1 (en) 2011-09-21
CA2744512C (en) 2018-05-15

Similar Documents

Publication Publication Date Title
AP3371A (en) Anti-IGF antibodies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
ZA201102119B (en) Improved antibody libraies
IL212701A0 (en) Improved anti-cd19 antibodies
GB0821100D0 (en) Antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
LT2853545T (lt) Antikūnai, specifiniai ige atžvilgiu
GB0708002D0 (en) Antibodies
GB0920127D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
GB0909906D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
ZA201101343B (en) Novel antibody formulation
ZA201006099B (en) Anti-tyrp1 antibodies
GB0702888D0 (en) Novel Antibodies
GB0718737D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
IL212900A0 (en) Isoform specific anti-her4 antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0911770D0 (en) Antibody
GB0823562D0 (en) Antibodies